Authors' objectives: Hepatocellular carcinoma (HCC) is a fast growing type of liver cancer that is usually caused by infection (e.g. hepatitis C) or liver damage (e.g. from alcohol). Treatment of HCC is often successful at first but may begin to fail over time, so that the cancer returns. Regorafenib is a new drug for the treatment of HCC that is given as a tablet. Some studies have suggested regorafenib may be helpful for people whose first treatment with a drug called sorafenib, has stopped working. More studies are now aiming to show how well it works and that it is safe to use. If regorafenib is licensed for use in the UK, it would be a new treatment available for patients that could improve survival when current treatments have stopped working.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/regorafenib-stivarga-for-hepatocellular-carcinoma-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)